Table 1 |
||
|
Approved anticancer drugs using nanocarriersa |
||
|
Trade name/compound |
Manufacturer |
Nanocarrier |
|
|
||
|
Abraxane/paclitaxel |
Abraxis Biosciences |
Albumin-bound paclitaxel |
|
Bexxar/anti-CD20 conjugated to iodine-131 |
Corixa/GlaxoSmithKline |
Radioimmunoconjugate |
|
DaunoXome/daunorubicin |
Diatos (available in France) |
Liposome |
|
Doxil/Caelyx/doxorubicin |
Ortho Biotech |
Liposome |
|
Myoset/doxorubicin |
Cephalon (available in Europe) |
Nonpegylated liposome |
|
Oncaspar/PEG-L-asparaginase |
Enzon |
Polymer-protein conjugate |
|
Ontak/IL-2 fused to diphtheria toxin |
Eisai Inc |
Immunotoxic fusion protein |
|
SMANCS/zinostatin |
Yamanouchi Pharma |
Polymer-protein conjugate |
|
Zevalin/anti-CD20 conjugated to yttrium-90 |
Cell Therapeutics Inc. |
Radioimmunoconjugate |
|
Zoladex/goserelin acetate |
AstraZeneca |
Polymer rods |
|
|
||
|
aPEG, polyethylene glycol; IL-2, interleukin-2; SMANCS, styrene maleic anhydride neocarzinostatin. Reproduced by permission © Jain PharmaBiotech. |
||
|
Jain BMC Medicine 2010 8:83 doi:10.1186/1741-7015-8-83 |
||
